Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

kennedykrieger.org

Total trials

75

Active

24

Phase 3

2

Total enrollment

15,140

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 2 of 2 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
methylphenidate hydrochloride1
Melatonin1

Next readouts

  • 2028-07-01
  • 2030-12

Top conditions

  • Autism Spectrum Disorder12
  • ADHD6
  • Anxiety5
  • Spinal Cord Injury5
  • Spinal Cord Injuries4
  • Autism3
  • Cerebellar Ataxia3
  • Stroke3

Frequently asked questions about Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

How many clinical trials does Hugo W. Moser Research Institute at Kennedy Krieger, Inc. have on ClinicalTrials.gov?
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
How many of Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s trials are in Phase 3?
2 of Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s trials are in Phase 3, spread across 2 active drug programs.
What therapeutic areas does Hugo W. Moser Research Institute at Kennedy Krieger, Inc. focus on?
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s most-studied conditions on ClinicalTrials.gov are Autism Spectrum Disorder, ADHD, Anxiety, Spinal Cord Injury, Spinal Cord Injuries.
When are Hugo W. Moser Research Institute at Kennedy Krieger, Inc.'s next clinical trial readouts?
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. has 2 upcoming primary-completion readouts tracked here; the soonest is “Melatonin for the Treatment of DEE-SWAS”, expected around 2028-07-01.